Regulation of Autophagy by Non-Steroidal Anti-Inflammatory Drugs in Cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. doi:10.3322/caac.2159031912902
   PubMed Web of Science ®Google Scholar
• Marino G, Niso-Santano M, Baehrecke EH, et al. Self-consumption: the interplay of autophagy and apoptosis. Nat Rev Mol Cell Biol. 2014;15:e81. doi:10.1038/nrm3735
   PubMed Web of Science ®Google Scholar
• Yazdani HO, Huang H, Tsung A. Autophagy: dual response in the development of hepatocellular carcinoma. Cells. 2019;8:e91. doi:10.3390/cells802009130695997
   PubMed Web of Science ®Google Scholar
• Wilde L, Tanson K, Curry J, et al. Autophagy in cancer: a complex relationship. Biochem J. 2018;475:1939–1954. doi:10.1042/BCJ2017084729891531
   PubMed Web of Science ®Google Scholar
• Kondo Y, Kanzawa T, Sawaya R, et al. The role of autophagy in cancer development and response to therapy. Nat Rev Cancer. 2005;5(9):e726. doi:10.1038/nrc1692
   PubMed Web of Science ®Google Scholar
• Yu L, Strandberg L, Lenardo MJ. The selectivity of autophagy and its role in cell death and survival. Autophagy. 2008;4(5):567–573. doi:10.4161/auto.590218362514
   PubMed Web of Science ®Google Scholar
• Rabinowitz JD, White E. Autophagy and metabolism. Science. 2010;330(6009):1344–1348. doi:10.1126/science.119349721127245
   PubMed Web of Science ®Google Scholar
• Doherty J, Baehrecke EH. Life, death and autophagy. Nat Cell Biol. 2018;20:1110–1117. doi:10.1038/s41556-018-0201-530224761
   PubMed Web of Science ®Google Scholar
• Singh SS, Vats S, Chia AYQ, et al. Dual role of autophagy in hallmarks of cancer. Oncogene. 2018;37(9):e1142. doi:10.1038/s41388-017-0046-6
   PubMed Web of Science ®Google Scholar
• Lorente J, Velandia C, Leal JA, et al. The interplay between autophagy and tumorigenesis: exploiting autophagy as a means of anticancer therapy. Biol Rev. 2018;93(1):152–165. doi:10.1111/brv.1233728464404
   PubMed Web of Science ®Google Scholar
• Wong RSY. Role of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) in cancer prevention and cancer promotion. Adv Pharmacol Sci. 2019;e2019.
   Web of Science ®Google Scholar
• Ulrich CM, Bigler J, Potter JD. Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer. 2006;6(2):e130. doi:10.1038/nrc1801
   PubMed Web of Science ®Google Scholar
• Wakabayashi K. NSAIDs as cancer preventive agents. Asian Pac J Cancer Prev. 2000;1(2):97–113.12718676
   PubMedGoogle Scholar
• Cuzick J, Otto F, Baron JA, et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol. 2009;10(5):501–507. doi:10.1016/S1470-2045(09)70035-X19410194
   PubMed Web of Science ®Google Scholar
• Zhang Z, Chen F, Shang L. Advances in antitumor effects of NSAIDs. Cancer Manag Res. 2018;10:e4631. doi:10.2147/CMAR.S175212
   PubMed Web of Science ®Google Scholar
• Lucotti S, Cerutti C, Soyer M, et al. Aspirin blocks formation of metastatic intravascular niches by inhibiting platelet-derived COX-1/thromboxaneA2. J Clin Invest. 2019;129:5. doi:10.1172/JCI121985
   Web of Science ®Google Scholar
• Jana NR. NSAIDs and apoptosis. Cell Mol Life Sci. 2008;65(9):1295–1301. doi:10.1007/s00018-008-7511-x18292966
   PubMed Web of Science ®Google Scholar
• Goel A, Chang DK, Ricciardiello L, et al. A novel mechanism for aspirin-mediated growth inhibition of human colon cancer cells. Clin Cancer Res. 2003;9(1):383–390.12538492
   PubMed Web of Science ®Google Scholar
• Zelenay S, Van Der Veen AG, Böttcher JP, et al. Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell. 2015;162(6):1257–1270. doi:10.1016/j.cell.2015.08.01526343581
   PubMed Web of Science ®Google Scholar
• Gurpinar E, Grizzle WE, Piazza GA. NSAIDs inhibit tumorigenesis, but how? Clin Cancer Res. 2014;20(5):1104–1113. doi:10.1158/1078-0432.CCR-13-157324311630
   PubMed Web of Science ®Google Scholar
• Yu C, Li W, Liu J, et al. Autophagy: novel applications of nonsteroidal anti-inflammatory drugs for primary cancer. Cancer Med. 2018;7(2):471–484. doi:10.1002/cam4.128729282893
   PubMed Web of Science ®Google Scholar
• Gunaydin C, Bilge SS. Effects of nonsteroidal anti-inflammatory drugs at the molecular level. Eurasian j Med. 2018;50(2):e116. doi:10.5152/eurasianjmed.2018.0010
   PubMed Web of Science ®Google Scholar
• Rouzer CA, Marnett LJ. Cyclooxygenases: structural and functional insights. J Lipid Res. 2009;50(Supplement):S29–S34. doi:10.1194/jlr.R800042-JLR20018952571
   PubMed Web of Science ®Google Scholar
• Brune K, Patrignani P. New insights into the use of currently available non-steroidal anti-inflammatory drugs. J Pain Res. 2015;8:e105. doi:10.2147/JPR.S75160
   PubMed Web of Science ®Google Scholar
• Frölich JC. A classification of NSAIDs according to the relative inhibition of cyclooxygenase isoenzymes. Trends Pharmacol Sci. 1997;18(1):30–34. doi:10.1016/S0165-6147(96)01017-69114728
   PubMed Web of Science ®Google Scholar
• Morita I. Distinct functions of COX-1 and COX-2. Prostaglandins Other Lipid Mediat. 2002;68:165–175. doi:10.1016/S0090-6980(02)00029-112432916
   PubMed Web of Science ®Google Scholar
• Mohammed NA, El-Aleem SA, El-Hafiz HA, et al. Distribution of constitutive (COX-1) and inducible (COX-2) cyclooxygenase in postviral human liver cirrhosis: a possible role for COX-2 in the pathogenesis of liver cirrhosis. J Clin Pathol. 2004;57(4):350–354. doi:10.1136/jcp.2003.01212015047734
   PubMed Web of Science ®Google Scholar
• Crofford LJ. COX-1 and COX-2 tissue expression: implications and predictions. J Rheumatol Suppl. 1997;49:15–19.9249646
   PubMedGoogle Scholar
• Díaz-González F, Sánchez-Madrid F. NSAIDs: learning new tricks from old drugs. Eur J Immunol. 2015;45(3):679–686. doi:10.1002/eji.20144522225523026
   PubMed Web of Science ®Google Scholar
• Badri W, Miladi K, Nazari QA, et al. Encapsulation of NSAIDs for inflammation management: overview, progress, challenges and prospects. Int J Pharm. 2016;515(1–2):757–773. doi:10.1016/j.ijpharm.2016.11.00227829170
   PubMedGoogle Scholar
• Ngo SNT, Addison CJ. Are COX-2 selective NSAIDs associated with less GI, renal, and cardiovascular side effects: evidence from animals treated with NSAIDs. Annu Res Rev Biol. 2018;1–8.
   Google Scholar
• Domiati S, El-Mallah A, Ghoneim A, et al. Evaluation of anti-inflammatory, analgesic activities, and side effects of some pyrazole derivatives. Inflammopharmacology. 2016;24(4):163–172. doi:10.1007/s10787-016-0270-727342269
   PubMed Web of Science ®Google Scholar
• Flauaus C, Schmidtko A. Gastrointestinal and cardiovascular side effects of NSAIDs. PHARMAKON. 2017;5(1):61–68.
   Google Scholar
• Shah V. NSAIDs: are they all the same? Pharmacology. 2018;e4.
   Google Scholar
• Bibbins-Domingo K. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: US preventive services task force recommendation statement. Ann Intern Med. 2016;164(12):836–845. doi:10.7326/M16-057727064677
   PubMed Web of Science ®Google Scholar
• Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 2010;376(9754):1741–1750. doi:10.1016/S0140-6736(10)61543-720970847
   PubMed Web of Science ®Google Scholar
• Avivi D, Moshkowitz M, Detering E, et al. The role of low-dose aspirin in the prevention of colorectal cancer. Expert Opin Ther Targets. 2012;16(sup1):S51–S62. doi:10.1517/14728222.2011.64781022313430
   PubMed Web of Science ®Google Scholar
• Lochhead PJ, Chan AT. Aspirin and the Prevention of Colorectal Cancer[M]//Nsaids and Aspirin. Cham: Springer; 2016:219–240.
   Google Scholar
• Hua H, Zhang H, Kong Q, et al. Complex roles of the old drug aspirin in cancer chemoprevention and therapy. Med Res Rev. 2019;39(1):114–145. doi:10.1002/med.2151429855050
   PubMed Web of Science ®Google Scholar
• Xu XR, Yousef GM, Ni H. Cancer and platelet crosstalk: opportunities and challenges for aspirin and other antiplatelet agents. Blood. 2018;131(16):1777–1789. doi:10.1182/blood-2017-05-74318729519806
   PubMed Web of Science ®Google Scholar
• Tsoi KKF, Ho JMW, Chan FCH, et al. Long-term use of low-dose aspirin for cancer prevention: a 10-year population cohort study in Hong Kong. Int j Cancer. 2019;145(1):267–273.30575949
   PubMed Web of Science ®Google Scholar
• Samadder NJ, Kuwada SK, Boucher KM, et al. Association of sulindac and erlotinib vs placebo with colorectal neoplasia in familial adenomatous polyposis: secondary analysis of a randomized clinical trial. JAMA oncol. 2018;4(5):671–677. doi:10.1001/jamaoncol.2017.543129423501
   PubMed Web of Science ®Google Scholar
• Barnett RM, Borras E, Samadder NJ, et al. Chemoprevention in hereditary colorectal cancer syndromes Hereditary Colorectal Cancer. 1999;86(11): 2551–2563.
   Google Scholar
• Tołoczko-Iwaniuk N, Dziemiańczyk-Pakieła D, Nowaszewska BK, et al. Celecoxib in cancer therapy and prevention–review. Curr Drug Targets. 2019;20(3):302–315. doi:10.2174/138945011966618080312173730073924
   PubMed Web of Science ®Google Scholar
• Kanda A, Ebihara S, Takahashi H, et al. Loxoprofen sodium suppresses mouse tumor growth by inhibiting vascular endothelial growth factor. Acta Oncol (Madr). 2003;42(1):62–70. doi:10.1080/0891060310002258
   Web of Science ®Google Scholar
• Yao M, Zhou W, Sangha S, et al. Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer. Clin Cancer Res. 2005;11(4):1618–1628. doi:10.1158/1078-0432.CCR-04-169615746067
   PubMed Web of Science ®Google Scholar
• Ko J-H, Lee S-G, Yang W, et al. The application of embelin for cancer prevention and therapy. Molecules. 2018;23(3):e621. doi:10.3390/molecules2303062129522451
   PubMed Web of Science ®Google Scholar
• Hasima N, Ozpolat B. Regulation of autophagy by polyphenolic compounds as a potential therapeutic strategy for cancer. Cell Death Dis. 2014;5(11):e1509–e1509. doi:10.1038/cddis.2014.46725375374
   PubMedGoogle Scholar
• Dikic I, Elazar Z. Mechanism and medical implications of mammalian autophagy Nature Reviews Molecular Cell Biology. 2018:1.
   Google Scholar
• Marquez RT, Xu L. Bcl-2: beclin 1 complex: multiple, mechanisms regulating autophagy/apoptosis toggle switch. Am J Cancer Res. 2012;2(2):e214.
   PubMed Web of Science ®Google Scholar
• Hill SM, Wrobel L, Rubinsztein DC. Post-translational modifications of Beclin 1 provide multiple strategies for autophagy regulation. Cell Death Differ. 2018;1.
   Google Scholar
• Huang Z, Fang W, Liu W, et al. Aspirin induces Beclin-1-dependent autophagy of human hepatocellular carcinoma cell. Eur J Pharmacol. 2018;823:58–64. doi:10.1016/j.ejphar.2018.01.03129408091
   PubMed Web of Science ®Google Scholar
• Qian HR, Shi ZQ, Zhu HP, et al. Interplay between apoptosis and autophagy in colorectal cancer. Oncotarget. 2017;8(37):e 62759. doi:10.18632/oncotarget.18663
   Google Scholar
• Yu L, Chen Y, Tooze SA. Autophagy pathway: cellular and molecular mechanisms. Autophagy. 2018;14(2):207–215. doi:10.1080/15548627.2017.137883828933638
   PubMed Web of Science ®Google Scholar
• Din FVN, Valanciute A, Houde VP, et al. Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells. Gastroenterology. 2012;142(7):1504–1515. doi:10.1053/j.gastro.2012.02.05022406476
   PubMed Web of Science ®Google Scholar
• Wang XW, Zhang YJ. Targeting mTOR network in colorectal cancer therapy. World J Gastroenterol. 2014;20(15):e4178. doi:10.3748/wjg.v20.i15.4178
   PubMed Web of Science ®Google Scholar
• Zhao Q, Wang Z, Wang Z, et al. Aspirin may inhibit angiogenesis and induce autophagy by inhibiting mTOR signaling pathway in murine hepatocarcinoma and sarcoma models. Oncol Lett. 2016;12(4):2804–2810. doi:10.3892/ol.2016.501727698862
   PubMed Web of Science ®Google Scholar
• Yue W, Yang CS, DiPaola RS, et al. Repurposing of metformin and aspirin by targeting AMPK-mTOR and inflammation for pancreatic cancer prevention and treatment. Cancer Prev Res. 2014;7(4):388–397. doi:10.1158/1940-6207.CAPR-13-0337
   PubMed Web of Science ®Google Scholar
• Ralph SJ, Nozuhur S, Moreno-Sánchez R, et al. NSAID celecoxib: a potent mitochondrial pro-oxidant cytotoxic agent sensitizing metastatic cancers and cancer stem cells to chemotherapy. J Cancer Metastasis Treat. 2018;4(9):e49. doi:10.20517/2394-4722.2018.42
   Google Scholar
• Zhu X, Zhou M, Liu G, et al. Autophagy activated by the c-Jun N-terminal kinase-mediated pathway protects human prostate cancer PC3 cells from celecoxib-induced apoptosis. Exp Ther Med. 2017;13(5):2348–2354.28565848
   PubMed Web of Science ®Google Scholar
• Zhang C, Shi J, Mao S, et al. Role of p38 MAPK in enhanced human cancer cells killing by the combination of aspirin and ABT-737. J Cell Mol Med. 2015;19(2):408–417. doi:10.1111/jcmm.1246125388762
   PubMed Web of Science ®Google Scholar
• Crighton D, Wilkinson S, O’Prey J, et al. DRAM, a p53-induced modulator of autophagy, is critical for apoptosis. Cell. 2006;126(1):121–134. doi:10.1016/j.cell.2006.05.03416839881
   PubMed Web of Science ®Google Scholar
• Kang KB, Zhu C, Yong SK, et al. Enhanced sensitivity of celecoxib in human glioblastoma cells: induction of DNA damage leading to p53-dependent G 1 cell cycle arrest and autophagy. Mol Cancer. 2009;8(1):e66. doi:10.1186/1476-4598-8-66
   PubMed Web of Science ®Google Scholar
• Mazzanti R, Platini F, Bottini C, et al. Down-regulation of the HGF/MET autocrine loop induced by celecoxib and mediated by P-gp in MDR-positive human hepatocellular carcinoma cell line. Biochem Pharmacol. 2009;78(1):21–32. doi:10.1016/j.bcp.2009.03.01319447220
   PubMed Web of Science ®Google Scholar
• Niranjan R, Mishra KP, Thakur AK. Inhibition of Cyclooxygenase-2 (COX-2) initiates autophagy and potentiates MPTP-induced autophagic cell death of human neuroblastoma cells, SH-SY5Y: an inside in the pathology of parkinson’s disease. Mol Neurobiol. 2018;55(10):8038–8050. doi:10.1007/s12035-018-0950-y29498006
   PubMed Web of Science ®Google Scholar
• Zhou P, Li Y, Li B, et al. Autophagy inhibition enhances celecoxib-induced apoptosis in osteosarcoma. Cell Cycle. 2018;17(8):997–1006. doi:10.1080/15384101.2018.146767729884091
   PubMed Web of Science ®Google Scholar
• Vallecillo-Hernández J, Barrachina MD, Ortiz-Masiá D, et al. Indomethacin disrupts autophagic flux by inducing lysosomal dysfunction in gastric cancer cells and increases their sensitivity to cytotoxic drugs. Sci Rep. 2018;8(1):e3593. doi:10.1038/s41598-018-21455-1
   PubMed Web of Science ®Google Scholar
• Johnsen JI, Lindskog M, Ponthan F, et al. Cyclooxygenase-2 is expressed in neuroblastoma, and nonsteroidal anti-inflammatory drugs induce apoptosis and inhibit tumor growth in vivo. Cancer Res. 2004;64(20):7210–7215. doi:10.1158/0008-5472.CAN-04-179515492235
   PubMed Web of Science ®Google Scholar
• Lynch PM, Burke CA, Phillips R, et al. An international randomised trial of celecoxib versus celecoxib plus difluoromethylornithine in patients with familial adenomatous polyposis. Gut. 2016;65(2):286–295. doi:10.1136/gutjnl-2014-30723525792707
   PubMed Web of Science ®Google Scholar
• Huang S, Sinicrope F. Celecoxib-induced apoptosis is enhanced by ABT-737 and by inhibition of autophagy in human colorectal cancer cells. Autophagy. 2010;6(2):256–269. doi:10.4161/auto.6.2.1112420104024
   PubMed Web of Science ®Google Scholar
• Quinn BA. Novel Therapeutic Strategies for Pancreatic Cancer. VCU Scholars Compass. 2014:e3.
   Google Scholar
• Park GB, Jin DH, Kim D. Sequential treatment with celecoxib and bortezomib enhances the ER stress-mediated autophagy-associated cell death of colon cancer cells. Oncol Lett. 2018;16(4):4526–4536. doi:10.3892/ol.2018.923330214587
   PubMed Web of Science ®Google Scholar
• Zhu RT, Gutkind JS, Johnson DE, et al. PIK3CA mutations in colorectal and breast cancer: impact on oncogenesis and response to non-steroidal anti-inflammatory drugs Targeting Cell Survival Pathways to Enhance Response to Chemotherapy. 2019:123–144.
   Google Scholar
• Nitulescu GM, Van De Venter M, Nitulescu G, et al. The Akt pathway in oncology therapy and beyond. Int J Oncol. 2018;53(6):2319–2331. doi:10.3892/ijo.2018.459730334567
   PubMed Web of Science ®Google Scholar
• Moon H-J, Kim H-B, Lee S-H, et al. Sensitization of multidrug-resistant cancer cells to Hsp90 inhibitors by NSAIDs-induced apoptotic and autophagic cell death. Oncotarget. 2018;9(13):e11303. doi:10.18632/oncotarget.24130
   PubMedGoogle Scholar
• Raza MH, Siraj S, Arshad A, et al. ROS-modulated therapeutic approaches in cancer treatment. J Cancer Res Clin Oncol. 2017;143:1789–1809. doi:10.1007/s00432-017-2464-928647857
   PubMed Web of Science ®Google Scholar
• Simon HU, Haj-Yehia A, Levi-Schaffer F. Role of reactive oxygen species (ROS) in apoptosis induction. Apoptosis. 2000;5:415–418. doi:10.1023/A:100961622830411256882
   PubMed Web of Science ®Google Scholar
• de Sa Junior PL, Camara DAD, Porcacchia AS, et al. The roles of ROS in cancer heterogeneity and therapy. Oxid Med Cell Longev. 2017;e2467940.
   PubMed Web of Science ®Google Scholar
• Poillet-Perez L, Despouy G, Delage-Mourroux R, Boyer-Guittaut M. Interplay between ROS and autophagy in cancer cells, from tumor initiation to cancer therapy. Redox Biol. 2015;4:184–219. doi:10.1016/j.redox.2014.12.00325590798
   PubMed Web of Science ®Google Scholar
• Zhou H, Yuan M, Yu Q, et al. Autophagy regulation and its role in gastric cancer and colorectal cancer. Cancer Biomark. 2016;17(1):1–10. doi:10.3233/CBM-16061327314289
   PubMed Web of Science ®Google Scholar
• Thomas S, Sharma N, Golden EB, et al. Preferential killing of triple-negative breast cancer cells in vitro and in vivo when pharmacological aggravators of endoplasmic reticulum stress are combined with autophagy inhibitors. Cancer Lett. 2012;325(1):63–71. doi:10.1016/j.canlet.2012.05.03022664238
   PubMed Web of Science ®Google Scholar
• Gao M, Yeh PY, Lu YS, et al. OSU-03012, a novel celecoxib derivative, induces reactive oxygen species–related autophagy in hepatocellular carcinoma. Cancer Res. 2008;68(22):9348–9357. doi:10.1158/0008-5472.CAN-08-164219010909
   PubMed Web of Science ®Google Scholar
• Moon H-J, Park S-Y, Lee S-H, et al. Nonsteroidal anti-inflammatory drugs sensitize CD44-overexpressing cancer cells to Hsp90 inhibitor through autophagy activation. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics. 2019;27(7):835–847. doi:10.3727/096504019X15517850319579
   Google Scholar
• Huang KH, Kuo KL, Ho IL, et al. Celecoxib-induced cytotoxic effect is potentiated by inhibition of autophagy in human urothelial carcinoma cells. PLoS One. 2013;8(12):e82034. doi:10.1371/journal.pone.008203424349176
   PubMed Web of Science ®Google Scholar
• Lu Y, Liu XF, Liu TR, et al. Celecoxib exerts antitumor effects in HL-60 acute leukemia cells and inhibits autophagy by affecting lysosome function. Biomed Pharmacother. 2016;84:1551–1557. doi:10.1016/j.biopha.2016.11.02627884749
   PubMed Web of Science ®Google Scholar
• Zhang X, Feng H, Du J, et al. Aspirin promotes apoptosis and inhibits proliferation by blocking G0/G1 into S phase in rheumatoid arthritis fibroblast-like synoviocytes via downregulation of JAK/STAT3 and NF-κB signaling pathway. Int J Mol Med. 2018;42(6):3135–3148. doi:10.3892/ijmm.2018.388330221683
   PubMed Web of Science ®Google Scholar
• Liu S, Tang Y, Yan M, et al. PIK3CA mutation sensitizes breast cancer cells to synergistic therapy of PI3K inhibition and AMPK activation. Invest New Drugs. 2018;36(5):763–772. doi:10.1007/s10637-018-0563-329504069
   PubMed Web of Science ®Google Scholar
• Olejniczak-Kęder A, Szaryńska M, Wrońska A, et al. Effects of 5-FU and anti-EGFR antibody in combination with ASA on the spherical culture system of HCT116 and HT29 colorectal cancer cell lines. Int J Oncol. 2019;55(1):223–242. doi:10.3892/ijo.2019.480931180528
   PubMed Web of Science ®Google Scholar
• Levy JMM, Thorburn A. Targeting autophagy during cancer therapy to improve clinical outcomes. Pharmacol Ther. 2011;131(1):130–141. doi:10.1016/j.pharmthera.2011.03.00921440002
   PubMed Web of Science ®Google Scholar
• Baehrecke EH. Autophagy: dual roles in life and death? Nat Rev Mol Cell Biol. 2005;6(6):e505. doi:10.1038/nrm1666
   PubMed Web of Science ®Google Scholar
• Bhat P, Kriel J, Priya BS, et al. Modulating autophagy in cancer therapy: advancements and challenges for cancer cell death sensitization. Biochem Pharmacol. 2018;147:170–182. doi:10.1016/j.bcp.2017.11.02129203368
   PubMed Web of Science ®Google Scholar
• Qi L, Ye JW, Xue WH, et al. The mechanism of aspirin combined with metformin induced apoptosis of thyroid cancer TPC-1 cells. Chin j Oncol. 2019;41(4):276–281. doi:10.3760/cma.j.issn.0253-3766.2019.04.006
   Google Scholar
• Williams CS, Goldman AP, Sheng H, Morrow JD, DuBois RN. Sulindac sulfide, but not sulindac sulfone, inhibits colorectal cancer growth. Neoplasia. 1999;6(2):170–176. doi:10.1038/sj.neo.7900024
   Google Scholar
• Gurpinar E, Grizzle WE, Shacka JJ, et al. A novel sulindac derivative inhibits lung adenocarcinoma cell growth through suppression of Akt/mTOR signaling and induction of autophagy. Mol Cancer Ther. 2013;12(5):663–674. doi:10.1158/1535-7163.MCT-12-078523443799
   PubMed Web of Science ®Google Scholar
• Lim SC, Kim SM, Choi JE, et al. Sodium salicylate switches glucose depletion-induced necrosis to autophagy and inhibits high mobility group box protein 1 release in A549 lung adenocarcinoma cells. Oncol Rep. 2008;19(5):1165–1171.18425372
   PubMed Web of Science ®Google Scholar
• Bauvy C, Gane P, Arico S, et al. Autophagy delays sulindac sulfide-induced apoptosis in the human intestinal colon cancer cell line HT-29. Exp Cell Res. 2001;268(2):139–149. doi:10.1006/excr.2001.528511478840
   PubMed Web of Science ®Google Scholar
• Chiou SK, Hoa N, Ge L, et al. Nutrient availability alters the effect of autophagy on sulindac sulfide-induced colon cancer cell apoptosis. Gastroenterol Res Pract. 2012;2012.
   Web of Science ®Google Scholar
• Kola V, Mondal S, Mondal P. Investigation of cytotoxic activity of prepared PLGA nanoparticle formulations of meloxicam in HT29 colon cancer cell lines. Lat Am J Pharm. 2017;36(12):2379–2385.
   Web of Science ®Google Scholar
• Dong X, Li R, Xiu P, et al. Meloxicam executes its antitumor effects against hepatocellular carcinoma in COX-2-dependent and-independent pathways. PLoS One. 2014;9(3):e92864. doi:10.1371/journal.pone.009286424675684
   PubMed Web of Science ®Google Scholar
• Zhong J, Dong X, Xiu P, et al. Blocking autophagy enhances meloxicam lethality to hepatocellular carcinoma by promotion of endoplasmic reticulum stress. Cell Prolif. 2015;48(6):691–704. doi:10.1111/cpr.1222126481188
   PubMed Web of Science ®Google Scholar
• Silva J, Arantes-Rodrigues R, Pinto-Leite R, et al. Synergistic effect of carboplatin and piroxicam on two bladder cancer cell lines. Anticancer Res. 2017;37(4):1737–1745.28373436
   PubMed Web of Science ®Google Scholar
• Pang Q, Jin H, Qu K, et al. The effects of nonsteroidal anti-inflammatory drugs in the incident and recurrent risk of hepatocellular carcinoma: a meta-analysis. Onco Targets Ther. 2017;10(2017):4645–4656. doi:10.2147/OTT.S14315429033583
   PubMedGoogle Scholar